Search research articles
Contact Us
Filters
Showing results (61-70 of 87) with videos related to
Page
of 9
Sort By:
Practical Radiation Oncology
|
June 19, 2022
A Prospective Study of Magnetic Resonance Imaging-guided Focal Salvage High-dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients
Mark T Corkum, Gerard Morton, D Andrew Loblaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 9, 2020
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton, Merrylee McGuffin, Hans T Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy
Gerard Morton, Hans T Chung, Merrylee McGuffin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 3, 2018
Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life
Hima Bindu Musunuru, Laura D'Alimonte, Melanie Davidson, et al.
The British Journal of Radiology
|
November 29, 2017
Efficacy of a rectal spacer with prostate SABR-first UK experience
Raymond B King, Sarah Os Osman, Ciaran Fairmichael, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 11, 2025
Updated results of MR-assisted focal salvage HDR prostate brachytherapy: a prospective study
Gregory Paulin, Gerard Morton, Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 31, 2016
Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer
Hima Bindu Musunuru, Melanie Davidson, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 20, 2021
Dose Summation Strategies for External Beam Radiation Therapy and Brachytherapy in Gynecologic Malignancy: A Review from the NRG Oncology and NCTN Medical Physics Subcommittees
Hayeon Kim, Yongsook C Lee, Stanley H Benedict, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2021
Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost
Hima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 5, 2021
Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life
Hima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 87) with videos related to
Sort By:
Page
of 9
Practical Radiation Oncology
|
June 19, 2022
A Prospective Study of Magnetic Resonance Imaging-guided Focal Salvage High-dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients
Mark T Corkum, Gerard Morton, D Andrew Loblaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 9, 2020
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton, Merrylee McGuffin, Hans T Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy
Gerard Morton, Hans T Chung, Merrylee McGuffin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 3, 2018
Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life
Hima Bindu Musunuru, Laura D'Alimonte, Melanie Davidson, et al.
The British Journal of Radiology
|
November 29, 2017
Efficacy of a rectal spacer with prostate SABR-first UK experience
Raymond B King, Sarah Os Osman, Ciaran Fairmichael, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 11, 2025
Updated results of MR-assisted focal salvage HDR prostate brachytherapy: a prospective study
Gregory Paulin, Gerard Morton, Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 31, 2016
Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer
Hima Bindu Musunuru, Melanie Davidson, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 20, 2021
Dose Summation Strategies for External Beam Radiation Therapy and Brachytherapy in Gynecologic Malignancy: A Review from the NRG Oncology and NCTN Medical Physics Subcommittees
Hayeon Kim, Yongsook C Lee, Stanley H Benedict, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2021
Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost
Hima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 5, 2021
Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life
Hima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Page
of 9